Literature DB >> 18221156

Poxvirus cancer therapy.

Philippe-Alexandre Gilbert1, Grant McFadden.   

Abstract

Despite many advances in chemotherapy and other medical techniques, patients with cancer often develop local recurrence or metastatic spread. Recent advances in molecular biology and tumor immunology have led to the design of many new anti-tumor vaccines. Such approaches are now using recombinant viruses to treat different types of cancer. From these new developments, innovative fields are emerging: vaccine virotherapy, viral immunotherapy, oncolytic virotherapy and drug virotherapy. Many viruses are currently exploited as recombinant vectors and each offers natural or synthetic characteristics that may provide unique means to treat cancer. Poxviruses are large double stranded DNA viruses that offer many advantageous characteristics as recombinant vectors. Poxvirus-based vectors offer essentially unlimited possibilities for genetic manipulation due to the large size of their DNA and high degree of safety. Vaccinia virus, the prototype virus of the Orthopoxvirus genus that was extensively used to eradicate Smallpox, and other poxviruses are now being considered and used for the treatment of cancer. This review will cover their utilization as anti-cancer therapeutics by describing recent patents (2000-2005).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18221156     DOI: 10.2174/157489106778777592

Source DB:  PubMed          Journal:  Recent Pat Antiinfect Drug Discov        ISSN: 1574-891X


  7 in total

Review 1.  Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus.

Authors:  Masmudur M Rahman; Gerard J Madlambayan; Christopher R Cogle; Grant McFadden
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-07       Impact factor: 7.638

2.  Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.

Authors:  Yu-Qian Zhang; Ya-Chea Tsai; Archana Monie; T-C Wu; Chien-Fu Hung
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

3.  Direct presentation is sufficient for an efficient anti-viral CD8+ T cell response.

Authors:  Ren-Huan Xu; Sanda Remakus; Xueying Ma; Felicia Roscoe; Luis J Sigal
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

4.  Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Authors:  Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

5.  A selectable and excisable marker system for the rapid creation of recombinant poxviruses.

Authors:  Julia L Rintoul; Jiahu Wang; Don B Gammon; Nicholas J van Buuren; Kenneth Garson; Karen Jardine; Michele Barry; David H Evans; John C Bell
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

6.  Induction of Cell Death in the Human Acute Lymphoblastic Leukemia Cell Line Reh by Infection with Rotavirus Isolate Wt1-5.

Authors:  Rafael Guerrero; Carlos Guerrero; Orlando Acosta
Journal:  Biomedicines       Date:  2020-07-24

7.  Transcriptomic profiles of high and low antibody responders to smallpox vaccine.

Authors:  R B Kennedy; A L Oberg; I G Ovsyannikova; I H Haralambieva; D Grill; G A Poland
Journal:  Genes Immun       Date:  2013-04-18       Impact factor: 2.676

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.